However, the present study has a limitation in that the precise pharmaceutical target of the BMP−ID2 cascade has not been well characterized, making it difficult to discern the mechanism of action underlying the anticancer activities of apigenin, particularly regarding combination therapy with the CDK1 inhibitor RO-3306 for the clinical management of BC. The gene discussed is CDK1; the disease is breast cancer.